Edivoxetine Did Not Meet Primary Endpoint in Major Depressive Disorder Study

Eli Lilly and Company announced that the primary study objective from three studies of edivoxetine for superior efficacy was not met in depression after eight weeks of treatment. Edivoxetine  is a highly selective norepinephrine reuptake inhibitor (SSRI) being studied as adjunctive treatment in patients with major depressive disorder (MDD).

RELATED: Psychiatric Disorders Resource Center

In 2010, Lilly launched the Phase 3 program for edivoxetine to focus on meeting the unmet needs of patients with major depression who had achieved only a partial response to treatment with an SSRI.  In these three trials, patients remained on SSRI treatment and additionally received either edivoxetine or placebo.  When added to a SSRI, edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale (MADRS) in the three acute randomized placebo-controlled Phase 3 studies (LNBM, LNBQ and LNBR).

The efficacy results did not support regulatory submission as adjunctive treatment in patients with major depressive disorder.

For more information call (800) 545-5979 or visit Lilly.com.